What Is AMD Vision and How Does It Affect Sight?

Age-related macular degeneration, usually called AMD, is a disease that gradually destroys the macula, the small area at the center of the retina responsible for sharp, detailed vision. It does not cause total blindness, but it erodes exactly the kind of sight people rely on most: reading, recognizing faces, driving, and seeing fine detail. AMD is the leading cause of severe vision loss in older adults in developed countries, and it comes in two forms, dry and wet, that damage the eye through different mechanisms and progress at very different speeds.

The Part of the Eye That AMD Targets

The macula sits in the center of the retina and contains a dense concentration of photoreceptors, the light-sensing cells that translate images into signals your brain can interpret. Just beneath those photoreceptors lies a single-cell-thick layer called the retinal pigment epithelium, or RPE. The RPE acts as a support system: it feeds the photoreceptors, clears away waste products, and helps maintain the blood supply from the layer of tiny vessels underneath it called the choriocapillaris.¹ When the RPE begins to break down, the photoreceptors lose their support and eventually die. That breakdown is the central event in AMD.²

The fovea, the very center of the macula, is the spot that gives you your sharpest vision. When you look directly at something, the image falls on the fovea. That is why AMD is so disabling even though it affects only a small physical area of the retina: it knocks out the highest-resolution part of the visual system while leaving peripheral vision mostly intact.

Dry AMD and How It Progresses

Roughly 85 to 90 percent of people with AMD have the dry form. It begins when yellowish deposits called drusen accumulate beneath the RPE. These drusen are made up of fats and proteins, many of them secreted by RPE cells themselves, that build up on a membrane called Bruch’s membrane over decades.³ In early stages, small drusen may cause no noticeable symptoms at all. Many people have a few small drusen by middle age and never develop meaningful vision loss.

The trouble starts when drusen become larger and more numerous, or when patches of the RPE begin to thin and die. That thinning can progress to geographic atrophy, the advanced form of dry AMD. Geographic atrophy means well-defined zones of the retina where the RPE, photoreceptors, and underlying blood vessels have all been lost. Those zones expand over time, and the complement system, part of the body’s immune response, appears to play a major role in driving that expansion through chronic inflammation.⁴

One oddity of geographic atrophy is that it tends to spare the very center of the macula, the fovea, longer than the surrounding area. Atrophy spreads roughly three times faster toward the periphery than toward the fovea.⁵ This foveal sparing can preserve reading vision for years even as surrounding tissue degenerates. Eventually, though, the atrophy typically does reach the fovea, and central vision drops substantially.

Wet AMD and Abnormal Blood Vessel Growth

Wet AMD accounts for a smaller share of cases but causes faster and more dramatic vision loss. In this form, new blood vessels begin growing from the choroid layer beneath the retina up through Bruch’s membrane and into spaces where they do not belong. These abnormal vessels are fragile. They leak fluid and blood under the retina, which can lift the retina away from its support layer and damage or kill photoreceptors rapidly.⁶ Where dry AMD can simmer for years before seriously affecting sight, wet AMD can cause noticeable vision loss within days or weeks of the new vessels appearing.

A protein called vascular endothelial growth factor, or VEGF, is a key driver of this abnormal vessel growth. VEGF signals the body to build new blood vessels, which is useful in wound healing but destructive when it happens under the retina. Drugs that block VEGF are the primary treatment for wet AMD, and they have transformed outcomes. But some patients do not respond well, suggesting that VEGF-independent pathways also contribute to the problem.⁶

Dry AMD can convert to wet AMD at any stage. When someone with dry AMD notices a sudden worsening of vision or new distortion, the most likely explanation is that wet AMD has developed, and that warrants urgent evaluation.

What AMD Actually Looks Like to the Person Who Has It

The experience of AMD is not like looking through a frosted window. The most characteristic early symptom is metamorphopsia, a distortion of shapes. Straight lines appear wavy or bent. Door frames might look curved, text on a page can seem to ripple, and faces may appear lopsided.⁷ This distortion happens because fluid or structural changes in the macula physically displace photoreceptors, so the brain receives a warped map of whatever the eye is looking at.⁸

As the disease advances, a central scotoma develops: a dark or blank spot right in the middle of your visual field. In advanced AMD, this scotoma can span the central 15 to 20 degrees of vision and frequently affects both eyes.⁹ Imagine trying to read a sentence but not being able to see the word you are looking directly at, only the words on either side. That is the functional reality. Peripheral vision remains, so people can still navigate rooms, avoid obstacles, and see general shapes, but the detail at the center is missing.

A less well-known effect is Charles Bonnet syndrome. Some people with AMD experience vivid, complex visual hallucinations: patterns, faces, animals, or landscapes that are not there. These are not psychiatric symptoms. They arise because the brain, deprived of normal visual input from the damaged macula, generates its own images to fill the gap. The syndrome is surprisingly common among AMD patients, and many are reluctant to mention it because they worry it signals a mental health disorder.¹⁰ Knowing this can happen, and that it does not mean anything is wrong with your thinking, is one of the most reassuring things a person newly diagnosed with AMD can hear.

Who Is Most at Risk

Age is the strongest non-modifiable risk factor. AMD rarely causes symptoms before the mid-50s and becomes increasingly common with each decade beyond that. But cigarette smoking is the strongest modifiable risk factor, and the evidence on this is unambiguous.¹¹ Cigarette smoke floods the retina with pro-oxidant compounds. Cadmium in tobacco accumulates in the RPE and choroid. Hydroquinone, the most abundant oxidant in smoke, disrupts the RPE’s balance of growth factors in a way that directly promotes the abnormal blood vessel growth seen in wet AMD.¹² Quitting smoking is the single most impactful lifestyle choice a person at risk for AMD can make.

Genetics also plays a substantial role. Two gene regions stand out in the research: complement factor H (CFH) and ARMS2. Carrying more risk alleles at these loci raises the likelihood of developing AMD in a dose-dependent way. In the long-running Beaver Dam Eye Study, the five-year incidence of late AMD ranged from about 1 percent in the low genetic risk group to about 6 percent in the high-risk group.¹³ That is a meaningful difference, but it also means that most people, even in the high-risk group, do not progress to late AMD within five years. Genetics loads the gun; age, smoking, and other factors pull the trigger.

How AMD Is Detected

Optical coherence tomography, commonly called OCT, is the gold standard for diagnosing and monitoring AMD.¹⁴ It uses light waves to create a cross-sectional image of the retina, revealing drusen, fluid, thinning of the RPE, and new vessel growth with remarkable detail. Most retinal specialists rely on OCT at every visit to track whether the disease is stable or changing.

At home, many patients use the Amsler grid, a simple sheet of evenly spaced lines you stare at with one eye at a time. If the lines look wavy, broken, or blurred, that can signal macular changes. The grid is inexpensive and available anywhere, but its sensitivity is limited: it catches metamorphopsia reasonably well but is less reliable at detecting geographic atrophy or certain types of new vessel growth.¹⁵ In the HOME Study, patients who used a more sophisticated home monitoring device in addition to standard self-checks caught new vessel growth earlier, and about 87 percent of those eyes maintained visual acuity of 20/40 or better at the time the new vessels were detected.¹⁶ Early detection matters enormously in wet AMD, because treatment works best when started before significant scarring forms.

Artificial intelligence is beginning to change the diagnostic landscape as well. Deep learning models trained on retinal photographs can now distinguish dry from wet AMD with classification accuracy above 90 percent, and some models achieve near-perfect performance on certain subtypes.¹⁷ These tools are not replacing eye doctors, but they could eventually allow screening in settings where a retinal specialist is not available.

Treatment for Wet AMD

Anti-VEGF injections have been the standard treatment for wet AMD since the mid-2000s, and they remain the most effective option. The drugs, injected directly into the eye, block the growth signal that drives abnormal blood vessels. In clinical practice, patients who start anti-VEGF treatment gain meaningful vision early on. One study found a mean gain of about 14 letters on a standard eye chart at five years, with roughly 43 percent of treated eyes achieving driving-level vision of 20/40 or better.¹⁸ The greatest gains went to patients who started with the worst vision, which speaks to how much room there is for improvement when the disease is caught before everything is lost.

The long-term picture is more sobering. After the initial improvements, vision tends to decline slowly despite ongoing treatment, dropping by roughly one and a half letters per year on average.¹⁹ A study modeling lifetime outcomes estimated that only about 12 percent of patients retain driving vision and about 15 percent retain reading vision in at least one eye over their remaining lifespan. Younger age at diagnosis and more injections during the first year of treatment were both associated with better long-term results.²⁰ The treatment burden is real: patients average around ten injections per year, and each injection visit involves travel, waiting, and the injection itself. Newer anti-VEGF drugs with longer duration of action are reducing injection frequency for some patients, but no current therapy eliminates the need for ongoing monitoring.

Treatment for Dry AMD and Geographic Atrophy

Until recently, there was no approved treatment for dry AMD or geographic atrophy. That changed with the arrival of complement inhibitors, drugs that target the immune cascade implicated in RPE destruction. Pegcetacoplan, the first to reach the market, works by binding to complement factor C3, a protein that sits at the convergence point of three immune activation pathways. By blocking C3, the drug dampens the inflammatory signaling that drives tissue loss.²¹ In a phase 2 trial, monthly injections of pegcetacoplan reduced the growth rate of atrophic lesions by about 29 percent over 12 months compared with sham treatment, and the effect grew larger in the second six months, reaching a 45 percent reduction.²²

A second complement inhibitor, avacincaptad pegol, targets the downstream complement factor C5 rather than C3. Larger trials of both drugs confirmed they slow atrophy growth, but there is an important caveat: neither drug showed a clear improvement in overall visual function at the primary endpoints of those trials.²³ Slowing the physical expansion of dead tissue is not the same as preserving usable sight, at least not on the timelines studied so far. Whether the reduced growth rate translates into preserved reading or driving vision years down the line is the open question that will define whether these drugs are genuinely worth the injection burden. For now, they represent a cautious step forward rather than a breakthrough.

The Role of Nutritional Supplements

The AREDS formulation, a specific combination of vitamins and minerals developed through large clinical trials, is the most studied nutritional intervention for AMD. The updated AREDS2 formula replaced beta-carotene with lutein and zeaxanthin, two pigments that concentrate naturally in the macula. Over ten years, participants taking lutein and zeaxanthin had about a 9 percent lower risk of progressing to late AMD compared with those not taking them. When compared head-to-head against beta-carotene, lutein and zeaxanthin showed a 15 percent lower risk of progression.²⁴ The switch to lutein and zeaxanthin also eliminated a lung cancer risk that beta-carotene posed for current and former smokers.

The genetics story complicates supplementation in ways most people do not hear about. In the AREDS cohort, the benefit of the supplement depended strongly on a person’s CFH and ARMS2 genotype. People with certain CFH risk alleles did best with antioxidants alone and actually did worse when zinc was added. People with ARMS2 risk alleles benefited most from zinc-containing formulas and had worse outcomes with antioxidants alone. Those carrying high-risk versions of both genes derived no measurable benefit from any AREDS supplement category.²⁵ Genetic testing for these variants is commercially available but is not part of standard care for most AMD patients. The evidence is strong enough that it is worth discussing with your ophthalmologist if you have been diagnosed with intermediate or advanced dry AMD.

Adapting to Life with Central Vision Loss

Because AMD does not affect peripheral vision, most people retain enough functional sight to move around their homes, cook with some adaptation, and maintain independence. The challenge is fine-detail tasks. Low vision rehabilitation programs focus on exactly this gap. They teach people to use magnifying devices, large-print materials, screen-reading software, and eccentric viewing, a technique where you train yourself to look slightly off to one side so the image falls on a healthier part of the retina rather than the damaged fovea.²⁶ Adequate lighting becomes critical: task lighting that would seem overkill to someone with normal vision makes the difference between legibility and illegibility for someone with AMD.

Driving is often the first major activity affected. Most jurisdictions require corrected vision of 20/40 in at least one eye for an unrestricted license, and many people with advanced AMD in both eyes no longer meet that threshold. Losing the ability to drive is consistently ranked by patients as one of the most distressing consequences of AMD, often more so than difficulty reading. Access to transportation alternatives and emotional support deserves as much clinical attention as the injections themselves.

The Gut-Retina Connection

A growing body of research is exploring whether the balance of bacteria in the gut influences AMD risk. The idea is not as far-fetched as it might sound. The gut microbiome shapes systemic inflammation, and AMD is fundamentally an inflammatory disease. In patients with wet AMD, researchers have found shifts in gut bacterial populations along with changes in microbial metabolic pathways, including reduced fatty acid production and increased activity in amino acid fermentation pathways.²⁷ In mouse models, high-fat diets worsened abnormal vessel growth by altering the gut microbiome and increasing pro-inflammatory signaling. The depletion of short-chain fatty acids and bile acids, metabolites produced by beneficial gut bacteria, has also been linked to advanced AMD progression.²⁸

This does not mean that taking a probiotic will prevent AMD. The research is still observational and early-stage, and no intervention trial has shown that modifying the gut microbiome changes AMD outcomes in humans. But it does reinforce something simpler: diet quality and systemic health are not separate from eye health. A diet high in leafy greens, fish, and fiber supports both a healthy microbiome and a healthy retina, and the mechanisms may be more directly connected than anyone appreciated a decade ago.